Trial reportPathology oncology research : POR2005
Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.
Trial report in Pathology oncology research : POR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Relationship between Prognosis, Immune Infiltration Level, and Differential Expression of PARVG Gene in Uterine Corpus Endometrial Carcinoma.Contrast media & molecular imaging · 2022Article
- Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.Cancer medicine · 2020Article
- B Cells and Antibodies in Kawasaki Disease.International journal of molecular sciences · 2019Review
- Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours.Contemporary oncology (Poznan, Poland) · 2018Article
- Harnessing the immune system in the battle against breast cancer.Drugs in context · 2018Review
- B lymphocytes and cancer: a love-hate relationship.Trends in cancer · 2016Review
- Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity.Frontiers in immunology · 2015Review
- Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer.Cancer immunology, immunotherapy : CII · 2015Article
- Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?Cancer immunology, immunotherapy : CII · 2014Review
- The immune microenvironment of human tumors: general significance and clinical impact.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013Article
- Tumor-infiltrating B cells come into vogue.World journal of gastroenterology · 2013Article
- Identification of novel tumor antigens with patient-derived immune-selected antibodies.Cancer immunology, immunotherapy : CII · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major focus of tumor immunology is to reveal the potential role and capacity of immunocompetent cells found in different solid tumor tissues. The most abundant infiltrating cells (TIL), the T lymphocytes have been investigated in details concerning T-cell receptor usage and specificity. However, B cells have hardly been investigated in this respect, although high cellular B-cell infiltration has been correlated with improved patients' survival in some breast carcinomas. This led to our objectives to study variable region gene usage of the tumor-infiltrating B cells in different breast carcinoma types. By defining the immunoglobulin repertoire of the tumor-infiltrating B lymphocytes in the most common invasive ductal carcinoma (IDC) of the breast we compared it to the rare medullary breast carcinoma (MBC). After phenotyping infiltrating ductal carcinomas, B cells were obtained from tumor tissue by microdissection technique. Numerous rearranged TIL-B immunoglobulin heavy chain V genes (VH) were amplified, cloned, sequenced, and comparatively analyzed. Some characteristics were found for both breast carcinoma types. The immunoglobulins produced by TIL-B in ductal carcinoma are highly matured and oligoclonal. We conclude that Ig variable region gene usage reveals similar and distinguishable characteristics of TIL-B immunoglobulin repertoires, which are representative of the nature of the immune responses in invasive ductal and medullary breast carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.